Idera Commences Phase Ib Trial for Lung Cancer Treatment
Posted on: Monday, 17 December 2007, 06:00 CST
Idera Pharmaceuticals has dosed the first patient in a Phase Ib trial evaluating IMO-2055, a novel agonist of Toll-like receptor 9 in combination with Tarceva and Avastin in patients with non-small cell lung cancer. Tarceva and Avastin are targeted agents approved by the FDA for this indication.
The Phase Ib trial evaluating IMO-2055 is being conducted in patients with advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed on first line chemotherapy. The trial is designed to assess safety of the IMO-2055, Tarceva and Avastin combination and to determine the recommended dose of IMO-2055 for use in the subsequent Phase II trial. Three doses of IMO-2055 are being investigated with standard doses and schedules of Tarceva and Avastin. IMO-2055 is administered subcutaneously once a week. The target enrollment for the trial is 40 patients.
Sudhir Agrawal, CEO and chief scientific officer, said: "Initiation of this Phase Ib trial in NSCLC is part of our previously announced oncology clinical development strategy. Following analysis of the Phase Ib results, we plan to conduct a four-arm randomized, placebo-controlled Phase II trial evaluating Tarceva alone, IMO-2055 and Tarceva, Tarceva and Avastin and IMO-2055, Tarceva and Avastin. Our preclinical studies have demonstrated increased antitumor activity when IMO-2055 is combined with approved targeted agents such as Avastin and Tarceva compared to the activity of any of these agents alone."
Source: Datamonitor
Related Articles
- Genentech and OSI Pharmaceuticals Announce Topline Results From Phase III Study Evaluating the Combination of Avastin and Tarceva As Second-Line Treatment for Advanced Non-Small Cell Lung Cancer
- MedImmune Initiates First Phase 2 Trial in Lupus Patients With Its Antibody Targeting Interferon-Alpha
- ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
- ChemGenex Initiates Omacetaxine Trial in AML Patients
- MedSpray 'Patch in a Can(R)' Technology Advances Towards Phase II Clinical Evaluation in Athlete's Foot
- Array BioPharma Advances ErbB-2 Inhibitor, ARRY-380, into Phase 1 Cancer Patient Trial
- Array BioPharma Advances P38 Inhibitor, ARRY-797, into Phase 1 Cancer Patient Trial
- Somaxon Pharmaceuticals, Inc. Initiates Second Phase III Clinical Trial of SILENOR(TM) -- Product Will Be Evaluated in Long-Term Trial of Elderly Patients With Primary Chronic Insomnia
- CVBT Announces It Will Begin U.S. FDA-Authorized Clinical Trials in Diabetic Patients With Open Wounds
- Predix Pharmaceuticals Announces Initiation of Phase Ib Clinical Trial in Alzheimer's Patients; Provides Initial Dose Study Update
 |
 |
User Comments (0)
RSS Feeds